Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024
Cooley M&A
JANUARY 23, 2024
With the licensing transactions that did occur in the biopharmaceutical industry in 2023, a majority occurred at the platform and discovery stages where the risk is significantly higher. Overall, there has been a decline in the number of R&D partnerships and licensing deals – volumes fell 15.4% billion.
52 
Let's personalize your content